



12-23-02

RECEIVED  
FEB 24 2003  
TECH CENTER 10624-053-999

Express Mail No.: EL 500 577 273

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Sakata et al.

Confirmation No.: 8859

Application No.: 10/071,390

Group Art Unit: 1755

Filed: February 7, 2002

Examiner: To Be Assigned

For: ISOTHIAZOLOANTHRONES,  
ISOXAZOLOANTHRONES,  
ISOINDOLANTHRONES AND  
DERIVATIVES THEREOF AS JNK  
INHIBITORS AND  
COMPOSITIONS AND METHODS  
RELATED THERETO

Attorney Docket No.: 10624-053-999

RECEIVED  
DEC 26 2002  
TC 1700

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing and prosecution of the above-identified application that are or may be related to patentability of the claimed invention, Attorneys for Applicants hereby direct the Examiner's attention to references **CI-CO** which are listed on the accompanying form PTO-1449 entitled "List of References Cited By Applicant." Copies of references **CI-CO** are submitted herewith. Identification of the listed references is not to be construed as an admission that such references are available as "prior art" against the subject application.

Applicants request that the Examiner review all the references identified on the attached form PTO-1449, and that they be made of record in the file history of the above-captioned application.

Pursuant to 37 C.F.R. §1.97(b), this Supplemental Information Disclosure Statement is being filed prior to the mailing date of a first Office Action on the merits, therefore, it is believed that no fee is required.

In the event that the Patent Office believes that a fee is due, please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.

Date December 20, 2002

Respectfully submitted,

*Anthony M. Insogna, Reg. No. 35,203*  
*By: Matthew E. Long, Reg. No. 36,343*  
*35,203*

Anthony M. Insogna

(Reg. No.)

PENNIE & EDMONDS LLP  
1155 Avenue of the Americas  
New York, New York 10036-2711  
(212) 790-9090

RECEIVED

Sheet 1 of 1

FEB 24 2003

Express Mail No.: EL 500 577 273 US



TECH CENTER 1600/2900

DOCKET NO.

10624-053-999

APPLICATION NO.

10/071,390

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT

Sakata et al.

FILING DATE

February 7, 2002

GROUP

1755

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
CI	WO 00/35909	6/22/00					
CJ	EP 0 208 211	1/14/87					

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

CK	CAS No. 130:153598d for Gwon et al., "Direct amination of 6H-anthra(9,1-cd)isothiazol-6-one 2,2-dioxides", Dokl. Akad. Nauk, 359:357-61, 1998.
CL	CAS No. 86:121031v for Shah et al., "Thiocyanation of 1-aminoanthraquinones", Indian J. Chem. 14B:625-626. 1976.
CM	CAS No. 102:205411f for Mitsubishi Chemical Industries Co., Ltd., JP 60 028,454
CN	CAS No. 104:208328m for Mitsubishi Chemical Industries Co., Ltd., JP 60 250,052
CO	CAS No. 103:143360y for Mitsubishi Chemical Industries Co., Ltd., JP 60 092,355

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED  
 DEC 26 2002  
 TC 1700